Nauck MA, DAlessio DA (2022) Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction
The 21-day clock continues regardless
You pull the vial out for your dose, set it down, and forget about it until morning
Ideal Candidates: Adults with a BMI of 30 or higher (obesity) Adults with a BMI of 27 or higher (overweight) with at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol Who is a Candidate
And that, even if [00:46:00] your Hashimoto's goes away, you know, you're done breastfeeding, you're done with your baby season, you still have that loss of function